| B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond. | B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.
Liongue C, Almohaisen FLJ, Ward AC., Free PMC Article | 11/4/2024 |
| Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. | Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation.
Li X, Sun W, Huang M, Gong L, Zhang X, Zhong L, Calderon V, Bian Z, He Y, Suh WK, Li Y, Song T, Zou Y, Lian ZX, Gu H. | 08/6/2024 |
| Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma. | Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma.
Gopalakrishnan V, Roy U, Srivastava S, Kariya KM, Sharma S, Javedakar SM, Choudhary B, Raghavan SC., Free PMC Article | 01/11/2024 |
| Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups? | Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
Blomme S, De Paepe P, Devos H, Emmerechts J, Snauwaert S, Cauwelier B. | 01/9/2024 |
| Bcl6 is a subset-defining transcription factor of lymphoid tissue inducer-like ILC3. | Bcl6 is a subset-defining transcription factor of lymphoid tissue inducer-like ILC3.
Tachó-Piñot R, Stamper CT, King JI, Matei-Rascu V, Richardson E, Li Z, Roberts LB, Bassett JW, Melo-Gonzalez F, Fiancette R, Lin IH, Dent A, Harada Y, Finlay C, Mjösberg J, Withers DR, Hepworth MR., Free PMC Article | 12/6/2023 |
| Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population. | Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population.
Xie C, Zhong L, Luo J, Luo J, Wu Y, Zheng S, Jiang L, Zhang J, Shi Y. | 09/6/2023 |
| B-cell lymphoma 6 expression significantly differs by the uterine preparation method used for frozen embryo transfer. | B-cell lymphoma 6 expression significantly differs by the uterine preparation method used for frozen embryo transfer.
Huang D, Chan M, Solomon M, Cedars MI, Giudice LC, Cakmak H. | 08/3/2023 |
| Clinical course and features of persistent polyclonal B-cell lymphocytosis with BCL-6 amplification during pregnancy. | Clinical course and features of persistent polyclonal B-cell lymphocytosis with BCL-6 amplification during pregnancy.
Galitzia A, Murru R, Caocci G, Barabino L, Azzena A, Licheri VM, Greco M, La Nasa G. | 05/11/2023 |
| Bcl6 drives stem-like memory macrophages differentiation to foster tumor progression. | Bcl6 drives stem-like memory macrophages differentiation to foster tumor progression.
Zhang W, Han Q, Ding Y, Zhou H, Chen Z, Wang J, Xiang J, Song Z, Abbas M, Shi L., Free PMC Article | 01/14/2023 |
| BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma. | BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma.
Fang SG, Xia TL, Fu JC, Li T, Zhong Q, Han F., Free PMC Article | 12/3/2022 |
| BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. | BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X., Free PMC Article | 11/26/2022 |
| BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis. | BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis.
Louwen F, Kreis NN, Ritter A, Friemel A, Solbach C, Yuan J., Free PMC Article | 11/12/2022 |
| A Bcl6 Intronic Element Regulates T Follicular Helper Cell Differentiation. | A Bcl6 Intronic Element Regulates T Follicular Helper Cell Differentiation.
Lai CY, Marcel N, Yaldiko AW, Delpoux A, Hedrick SM. | 10/8/2022 |
| LncRNA PCED1B-AS1 Upregulation in Hepatocellular Carcinoma and Regulation of the miR-10a/BCL6 Axis to Promote Cell Proliferation. | LncRNA PCED1B-AS1 Upregulation in Hepatocellular Carcinoma and Regulation of the miR-10a/BCL6 Axis to Promote Cell Proliferation.
Ding H, He J, Xiao W, Ren Z, Gao W. | 08/27/2022 |
| High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. | High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
Ferrari A, Arniani S, Crescenzi B, Ascani S, Flenghi L, Pierini V, Moretti M, Beacci D, Romoli S, Bardelli V, Calistri D, Martinelli G, Mecucci C, La Starza R. | 06/11/2022 |
| Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis. | Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis.
Mäkinen A, Nikkilä A, Mehtonen J, Teppo S, Oksa L, Nordlund J, Rounioja S, Pohjolainen V, Laukkanen S, Heinäniemi M, Paavonen T, Lohi O. | 05/21/2022 |
| miR-30b-5p inhibits osteoblast differentiation through targeting BCL6. | miR-30b-5p inhibits osteoblast differentiation through targeting BCL6.
Luo Y, Zhou F, Wu X, Li Y, Ye B., Free PMC Article | 04/30/2022 |
| Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. | Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L, Castrejon-de-Anta N, Ramis-Zaldivar JE, Streich S, Salmerón-Villalobos J, Otto F, Mayer AK, Steinhilber J, Pinyol M, Mankel B, Ramsower C, Bonzheim I, Fend F, Rimsza LM, Salaverria I, Campo E, Balagué O, Quintanilla-Martinez L., Free PMC Article | 04/23/2022 |
| Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis. | Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis.
Russo D, Travaglino A, Varricchio S, Pace M, Cretella P, Baldo A, Severino A, Picardi M, Mascolo M. | 04/16/2022 |
| An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. | An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.
Sultan M, Nearing JT, Brown JM, Huynh TT, Cruickshank BM, Lamoureaux E, Vidovic D, Dahn ML, Fernando W, Coyle KM, Giacomantonio CA, Langille MGI, Marcato P., Free PMC Article | 04/2/2022 |
| B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population. | B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population.
Klimczak AM, Herlihy NS, Scott CS, Hanson BM, Kim JG, Titus S, Seli E, Scott RT Jr. | 03/5/2022 |
| Defective STAT5 Activation and Aberrant Expression of BCL6 in Naive CD4 T Cells Enhances Follicular Th Cell-like Differentiation in Patients with Granulomatosis with Polyangiitis. | Defective STAT5 Activation and Aberrant Expression of BCL6 in Naive CD4 T Cells Enhances Follicular Th Cell-like Differentiation in Patients with Granulomatosis with Polyangiitis.
Kim S, Boehme L, Nel L, Casian A, Sangle S, Nova-Lamperti E, Seitan V, Spencer J, Lavender P, D'Cruz DP, John S. | 02/26/2022 |
| [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements]. | [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
Shen X, Zhou LT, Li AQ, Yi HM, Ouyang BS, Xu HM, Xie JL, Gu YJ, Zhang L, Dong L. | 02/19/2022 |
| MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis. | MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis.
Srivastava S, Makala H, Sharma V, Suri V, Sarkar C, Kulshreshtha R., Free PMC Article | 02/12/2022 |
| Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. | Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, López C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall'Olio R, Martínez-Martín S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamò A, Chiarle R., Free PMC Article | 01/15/2022 |